Capital Impact Advisors’s BridgeBio Pharma BBIO Stock Holding History

Capital Impact Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-13,925	Closed	-$353K	–	9
2024 Q2	$353K	Sell	13,925 -837	-6%	-$22.9K	0.99%	49
2024 Q1	$456K	Sell	14,762 -6,511	-31%	-$221K	0.59%	71
2023 Q4	$859K	Hold	21,273	–	–	1.13%	37
2023 Q3	$561K	Sell	21,273 -6,393	-23%	-$181K	0.94%	51
2023 Q2	$476K	Hold	27,666	–	–	0.52%	92
2023 Q1	$459K	Sell	27,666 -5,003	-15%	-$58.3K	0.56%	78
2022 Q4	$249K	Sell	32,669 -2,711	-8%	-$26K	0.24%	168
2022 Q3	$341K	Buy	35,380 +5,371	+18%	+$55.8K	0.34%	125
2022 Q2	$272K	Buy	+30,009	New	+$251K	0.25%	172

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Impact Advisors's BBIO Position: Q3 2024 in Review

Capital Impact Advisors sold out of BridgeBio Pharma (BBIO) in Q3 2024, closing a stake of 13,925 shares — an estimated $353K sold.

Capital Impact Advisors first reported a position in BBIO in Q2 2022 and held it in 9 quarters. The position peaked at $859K in Q4 2023. 253 funds tracked by Wall St. Rank hold BBIO as of Q3 2024.

Capital Impact Advisors reported no remaining BridgeBio Pharma position as of Q3 2024 after selling out during the quarter.
Capital Impact Advisors sold 13,925 BridgeBio Pharma shares in Q3 2024, an estimated $353K.
Capital Impact Advisors first reported a position in BridgeBio Pharma in Q2 2022 and held it in 9 quarters.
Capital Impact Advisors's BridgeBio Pharma position peaked at $859K in Q4 2023.
253 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2024.

Based on Capital Impact Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.